New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
14:51 EDTMDXGMiMedx addressed reimbursement fears on call, says Craig-Hallum
Craig-Hallum said MiMedx management outlined reimbursement scenarios for when the company no longer has pass-through status, calming the fears of some investors. Craig-Hallum also noted that the company raised the lower-end of its FY14 revenue guidance to $95M from $90M and that management said its meeting with the FDA about its micronized injectable products was both "productive and helpful." The firm reiterates its Buy rating and $10 price target on MiMedx.
News For MDXG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
07:06 EDTMDXGMiMedx Q2 results solid, says Brean Capital
Subscribe for More Information
July 30, 2015
07:45 EDTMDXGMiMedx backs FY15 revenue view $180M-$190M, consensus $187.44M
Sees FY15 operating margin 12%-14%.
07:44 EDTMDXGMiMedx sees Q3 revenue $47M-$50M, consensus $48.68M
Sees Q3 operating profit 13%-15%.
07:43 EDTMDXGMiMedx reports Q2 EPS 5c, consensus 5c
Reports Q2 revenue $45.7M, consensus $44.99M.
July 29, 2015
10:00 EDTMDXGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:28 EDTMDXGMiMedx downgraded to Buy from Strong Buy at Needham
Needham downgraded MiMedx to Buy from Strong Buy with a $15 price target. The firm said MiMedx faces more difficult comps the rest of the year and downgraded shares based on limited upside to consensus estimates and valuation.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use